Hooper Holmes Appoints Dr. Neil Gordon Corporate Medical Director

OLATHE, Kan.--()--Hooper Holmes (NYSE MKT:HH) has appointed a medical director with deep experience in evidence-based wellness programs to expand the Company’s biometric screening capabilities and develop new services.

“Dr. Gordon’s appointment expands our medical domain expertise and will help customers motivate and engage their program participants. He will play a leadership role on our team as we continue to develop new services.”

Dr. Neil F. Gordon, M.D., PhD, MPH, FACC, will oversee the medical content of Hooper’s screening programs and further improve the participant experience. He will help develop new services that draw upon his expertise in lifestyle management and chronic disease risk reduction, as well as upon the capabilities of Clinical Reference laboratory, Inc. (CRL), the Company’s strategic partner for laboratory testing services.

Henry E. Dubois, President and CEO of Hooper Holmes, commented, “Dr. Gordon’s appointment expands our medical domain expertise and will help customers motivate and engage their program participants. He will play a leadership role on our team as we continue to develop new services.”

Dr. Gordon has served as medical director for several corporate wellness providers and as a Clinical Professor of Medicine at the Emory University School of Medicine. He has also served as Vice President of the American Association for Cardiovascular and Pulmonary Rehabilitation, as a member of the Board of Trustees of the American College of Sports Medicine, and as Chairman of the American Heart Association Committee on Exercise, Cardiac Rehabilitation and Prevention.

Dr. Neil Gordon commented, “My career has been devoted to preventing cardiovascular disease and other chronic illnesses. Corporate wellness programs and clinical research have important roles to play in these efforts. Hooper is an acknowledged leader in biometric screenings for groups of any size and I am delighted to help Hooper and its customers change behavior, reduce risk and deliver measurable results.”

In 1997, Dr. Gordon became founder, CEO and chief science officer of INTERVENT USA, a provider of evidence-based, lifestyle management and chronic disease risk reduction services, which was acquired by Nationwide Better Health in April 2007. Dr. Gordon served as chief medical and science officer of Nationwide Better Health until 2011 when, under his leadership, INTERVENT International and its affiliate companies reacquired global rights. His role as CEO and chief science officer of INTERVENT International continues.

Dr. Gordon has served as principal investigator for research grants funded by the American Heart Association, the National Institutes of Health, and the American Diabetes Association. He is the author of eight books on preventive medicine and more than 100 scientific articles in peer-reviewed medical journals including the American Journal of Cardiology, British Heart Journal, Circulation, Journal of the American College of Cardiology, and the Journal of the American Medical Association. Dr. Gordon obtained his M.D. and a Ph.D. in exercise physiology in Johannesburg, South Africa, before relocating to the United States in 1987. He received his master’s degree in public health from the University of California, Los Angeles.

About Hooper Holmes

Hooper Holmes, Inc. mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions.

This press release contains “forward-looking” statements; as such term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions. Among the important factors that could cause actual results to differ materially from those expressed in, or implied by, these forward-looking statements are our ability to realize the expected benefits from our strategic alliance with Clinical Reference Laboratory; our ability to successfully implement our business strategy; our ability to retain and grow our customer base; our ability to recognize operational efficiencies and reduce costs; uncertainty as to our working capital requirements over the next 12 to 24 months; our ability to maintain compliance with the financial covenant in our credit facility; and the rate of growth in the Health and Wellness market. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s annual report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission on March 31, 2014. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release to reflect the occurrence of unanticipated events, except as required by law.

Contacts

Hooper Holmes
Henry E. Dubois, President and CEO, 913-764-1045
or
Investors:
S.M. Berger & Company
Andrew Berger, 216-464-6400